Dr. Anat Cohen-Dayag, President and CEO of Compugen, remarked, "We are very proud of the fact that our first market-driven discovery effort using our unique and broadly applicable predictive infrastructure built over the last decade resulted in the prediction of nine separate and distinct B7/CD28-like molecules, such as CGEN-15001T and CGEN-15022. These two novel molecules are now demonstrating significant potential as monoclonal antibody targets for immunotherapy, one of the most promising new approaches for the treatment of various cancers and an approach that has lately been the subject of great enthusiasm. For example, at the recent annual American Society of Clinical Oncology meeting, studies were reported demonstrating great promise for monoclonal antibodies based on this approach as a long-term therapy for cancer, resulting in widespread interest and media coverage."Dr. Cohen-Dayag continued, “In addition, the potential value of our B7/CD28-like discoveries is further substantially enhanced by the fact that five soluble proteins based on these molecules have demonstrated positive disease animal model results for various autoimmune diseases and are now under further development in our Pipeline Program."
Compugen Announces Validation Results For A Second Potential Immune Checkpoint Target For Cancer Immunotherapy
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.